175 related articles for article (PubMed ID: 26898432)
21. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
[TBL] [Abstract][Full Text] [Related]
24. Protein regulator of cytokinesis-1 expression: prognostic value in lung squamous cell carcinoma patients.
Zhan P; Xi GM; Liu HB; Liu YF; Xu WJ; Zhu Q; Zhou ZJ; Miao YY; Wang XX; Jin JJ; Lv TF; Song Y
J Thorac Dis; 2017 Jul; 9(7):2054-2060. PubMed ID: 28840006
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of long non-coding RNA HCG11 predicts a poor prognosis in prostate cancer.
Zhang Y; Zhang P; Wan X; Su X; Kong Z; Zhai Q; Xiang X; Li L; Li Y
Biomed Pharmacother; 2016 Oct; 83():936-941. PubMed ID: 27522256
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
28. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
29. Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
Zhou L; Xia D; Zhu J; Chen Y; Chen G; Mo R; Zeng Y; Dai Q; He H; Liang Y; Jiang F; Zhong W
Clin Transl Oncol; 2014 Oct; 16(10):906-13. PubMed ID: 24659377
[TBL] [Abstract][Full Text] [Related]
30. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
[TBL] [Abstract][Full Text] [Related]
32. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.
Spahn M; Kneitz S; Scholz CJ; Stenger N; Rüdiger T; Ströbel P; Riedmiller H; Kneitz B
Int J Cancer; 2010 Jul; 127(2):394-403. PubMed ID: 19585579
[TBL] [Abstract][Full Text] [Related]
33. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
34. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
35. miR-539 inhibits prostate cancer progression by directly targeting SPAG5.
Zhang H; Li S; Yang X; Qiao B; Zhang Z; Xu Y
J Exp Clin Cancer Res; 2016 Apr; 35():60. PubMed ID: 27037000
[TBL] [Abstract][Full Text] [Related]
36. SOXs in human prostate cancer: implication as progression and prognosis factors.
Zhong WD; Qin GQ; Dai QS; Han ZD; Chen SM; Ling XH; Fu X; Cai C; Chen JH; Chen XB; Lin ZY; Deng YH; Wu SL; He HC; Wu CL
BMC Cancer; 2012 Jun; 12():248. PubMed ID: 22703285
[TBL] [Abstract][Full Text] [Related]
37. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer.
Zhu JG; Yuan DB; Chen WH; Han ZD; Liang YX; Chen G; Fu X; Liang YK; Chen GX; Sun ZL; Liu ZZ; Chen JH; Jiang FN; Zhong WD
Clin Transl Oncol; 2016 Aug; 18(8):782-91. PubMed ID: 26563146
[TBL] [Abstract][Full Text] [Related]
40. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
